Jerry L. Spivak

Hematology
600 N Wolfe St
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications

Conflating polycythemia vera with essential thrombocytosis.

Conflating polycythemia vera with essential thrombocytosis.

Journal: Blood advances
Published: April 16, 2025

Myeloproliferative Neoplasms: Challenging Dogma.

Myeloproliferative Neoplasms: Challenging Dogma.

Journal: Journal of clinical medicine
Published: October 21, 2024

Sex specific definitions of anaemia reflect androgen production.

Sex specific definitions of anaemia reflect androgen production.

Journal: The Lancet. Haematology
Published: January 31, 2022

Advances in polycythemia vera and lessons for acute leukemia.

Advances in polycythemia vera and lessons for acute leukemia.

Journal: Best practice & research. Clinical haematology
Published: December 06, 2021

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.

HMGA1 chromatin regulators induce transcriptional networks involved in GATA2 and proliferation during MPN progression.

Journal: Blood
Published: September 03, 2021

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.

The Thrombopoietin Receptor, MPL, Is a Therapeutic Target of Opportunity in the MPN.

Journal: Frontiers in oncology
Published: December 14, 2020

Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?

Are polycythemia vera, essential thrombocytosis, and primary myelofibrosis 1, 2, or 3 diseases?

Journal: Leukemia
Published: November 03, 2020

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

Thrombopoietin is required for full phenotype expression in a JAK2V617F transgenic mouse model of polycythemia vera.

Journal: PloS one
Published: January 10, 2020

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden.

Sex determines the presentation and outcomes in MPN and is related to sex-specific differences in the mutational burden.

Journal: Blood advances
Published: December 26, 2019

Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?

Polycythaemia vera, ruxolitinib, and hydroxyurea: where do we go now?

Journal: The Lancet. Haematology
Published: November 18, 2019

Treatment of Iron Deficiency in the Elderly: A New Paradigm.

Treatment of Iron Deficiency in the Elderly: A New Paradigm.

Journal: Clinics in geriatric medicine
Published: June 25, 2019

Mutated CALR: tails from the crypt.

Mutated CALR: tails from the crypt.

Journal: Blood
Published: June 22, 2019
Showing 1-12 of 41

Last Updated: 09/26/2026